Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of Stock

by · The Cerbat Gem

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Rahul D. Ballal sold 10,420 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $28.17, for a total transaction of $293,531.40. Following the transaction, the director now owns 22,341 shares of the company’s stock, valued at approximately $629,345.97. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Enliven Therapeutics Stock Performance

ELVN stock traded down $1.24 during trading on Thursday, hitting $26.97. 255,173 shares of the company’s stock traded hands, compared to its average volume of 262,228. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $28.62. The business has a fifty day simple moving average of $23.34 and a 200 day simple moving average of $22.22. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -13.97 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Check Out Our Latest Stock Report on Enliven Therapeutics

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $9,657,000. American Century Companies Inc. lifted its holdings in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after acquiring an additional 8,540 shares during the last quarter. Finally, Nicholas Investment Partners LP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $1,310,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Articles